Does the maternal age affect the mesenchymal stem cell markers and gene expression in the human placenta? What is the evidence?

• CD105 expression in placental MSCs negatively correlated with the maternal age.
• CD29 expression in placental MSCs negatively correlated with the maternal age.
• CD105 MSCs are significantly abundant in the decidua basalis and placental villi.
• CD29 MSCs are significantly abundant in the decidua basalis and placental villi.

BackgroundAlthough the human placenta is considered medical wastes, it has become a main source of stem cells. Due to their easy isolation, ability to resist immune rejection and ability to differentiate into different types of adult cells, placental stem cells are considered superior to other stem cells.ObjectivesThis study aimed to assess the impact of the maternal age on the expression of mesenchymal stem cell (MSC) markers CD105 and CD29 in different areas of a term human placenta and to identify the differential expression of these markers in different placental areas.Subjects and methodsIn this comparative cross sectional study, one hundred term placentas were collected after delivery from healthy mothers divided into five groups according to their age. Placentas were processed to assess both immune- and gene-expression of CD105 and CD29 surface antigen markers. Data of the different studied age groups was compared using the Statistical Package of Social Science (SPSS) software.ResultsCD105 and CD29 immunoexpression in decidua basalis, fetal membrane and placental villi showed significant negative correlations with the maternal age. CD105- and CD29-positive MSCs were significantly abundant in the decidua basalis and placental villi. Real-time polymerase chain reaction results were consistent with those of the immunohistochemical study.ConclusionLabeling the placenta-driven MSCs with the specific area from which the cells were taken as well as the mother's age is advised and could be helpful in controlling the quality of the cell banks as well as the favorable outcome of the therapeutic applications.